33
Han X, Wang H, Chen L, Wang Y, Li H, Zhou F, Xing X, Zhang C, Suo L, Wang J, Yu G, Wang G, Yao X, Yu H, Wang L, Liu M, Xue C, Liu B, Zhu X, Li Y, Xiao Y, Cui X, Li L, Liu X*, Cao B*. Impact of inhaled corticosteroid use on elderly chronic pulmonary disease patients with community acquired pneumonia. Chin Med J (Engl). 2024 Jan 20;137(2):241-243. doi: 10.1097/CM9.0000000000002936.
34
Wang Y#, Guo L#, Cui D#, Zhang H#, Zhang Q, Ren L, Wang G, Zhang X, Huang T, Chen L, Huang L, Wang X, Zhong J, Wang Y, Li H, Wang J*, Cao B*. Immune Responses in Discharged COVID-19 Patients With and Without Long COVID Symptoms. Open Forum Infect Dis. 2024 Apr 1;11(4):ofae137. doi: 10.1093/ofid/ofae137.
35
Wang Y, Cao B. The insights from SARS-CoV-2 antibody treatment for future emerging infectious diseases. Lancet Infect Dis. 2024 Jan;24(1):2-3. doi: 10.1016/S1473-3099(23)00454-1.
36
Wang Y#, Kong Q#, Zhang Q, Ma T, An Y, Zhou YJ, Zhang X*, Cao B*. BPI23-Fcγ alleviates lethal multi-drug-resistant Acinetobacter baumannii infection by enhancing bactericidal activity and orchestrating neutrophil function. Int J Antimicrob Agents. 2024 Jan;63(1):107002. doi: 10.1016/j.ijantimicag.2023.107002.
37
Zhang H#, Huang C#, Gu X#, Wang Y#, Li X, Liu M, Wang Q, Xu J, Wang Y, Dai H, Zhang D*, Cao B*. 3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China: a longitudinal cohort study. Lancet Respir Med. 2024 Jan;12(1):55-66. doi: 10.1016/S2213-2600(23)00387-9.
38
Cao B#*, Wang Y#, Lu H#, Huang C#, Yang Y#, Shang L, Chen Z, Jiang R, Liu Y, Lin L, Peng P, Wang F, Gong F, Hu H, Cheng C, Yao X, Ye X, Zhou H, Shen Y, Liu C, Wang C, Yi Z, Hu B, Xu J, Gu X, Shen J, Xu Y, Zhang L, Fan J, Tang R*, Wang C*. Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19. N Engl J Med. 2024 Jan 18;390(3):230-241. doi: 10.1056/NEJMoa2301425. PMID: 38231624.
39
Zhao J#, Zhuo X#, Pu D, Fan G, Lu B*, and Cao B*. Comparison of influenza‐ and COVID‐19‐associated pulmonary aspergillosis in China. European Journal of Clinical Microbiology & Infectious Diseases. 2024 doi: 10.1007/s10096-024-04772-4
40
Fan G#, Zhou Y#, Zhou F, Yu Z, Gu X, Zhang X, Liu Z, Zhou M*, Cao B*. The mortality and years of life lost for community-acquired pneumonia before and during COVID-19 pandemic in China. Lancet Reg Health West Pac. 2023 doi: 10.1016/j.lanwpc.2023.100968.
41
Zhao J#, Pu D#, Li Z, Liu X, Zhang Y, Wu Y, Zhang F, Li C, Zhuo X, Lu B, Cao B*. In vitro activity of cefiderocol, a siderophore cephalosporin, against carbapenem-resistant hypervirulent Klebsiella pneumoniae in China. Antimicrob Agents Chemother. 2023 doi: 10.1128/aac.00735-23.
42
Gu X#, Wang S#, Zhang W#, Li C#, Guo L#, Wang Z, Li H, Zhang H, Zhou Y, Liang W, Li H, Liu Y, Wang Y, Huang L, Dong T, Zhang D*, Wong CCL*, Cao B*. Probing long COVID through a proteomic lens: a comprehensive two-year longitudinal cohort study of hospitalised survivors. EBioMedicine. 2023 doi: 10.1016/j.ebiom.2023.104851.
43
Pu D, Zhao J, Chang K, Zhuo X, Cao B*. "Superbugs" with hypervirulence and carbapenem resistance in Klebsiella pneumoniae: the rise of such emerging nosocomial pathogens in China. Sci Bull (Beijing). 2023 doi: 10.1016/j.scib.2023.09.040.
44
Yan M, Zou X, Wang Y, Wang C, Wang Y, Liu Z, Shang L, Cui X, Cao B. Metagenomic next-generation sequencing (mNGS) of bronchoalveolar lavage fluid on antimicrobial stewardship in patients with lower respiratory tract infections (LRTIs): a retrospective cohort study. J Infect Dis. doi: 10.1093/infdis/jiad296.
45
Zhao J#, Pu D#, Zhang Y, Qu J, Lu B, Cao B*. Comparison of Performances of GeneXpert MTB/RIF, Bactec MGIT 960, and Bactec Myco/F Systems in Detecting Mycobacterium tuberculosis in Biopsy Tissues: a Retrospective Study. Microbiology Spectrum. 2023. doi: 10.1128/spectrum.01414-22.
46
Xu J, Cao B*. Appropriate use of antimicrobials in primary healthcare facility: a long way to go. Clinical Microbiology and Infection. 2023;29(5):563-4. doi: 10.1016/j.cmi.2023.02.010.
47
Wu X#, Xuan W#, Yang X, Liu W, Zhang H, Jiang G, Cao B*, Jiang Y*. Ficolin A knockout alleviates sepsis-induced severe lung injury in mice by restoring gut Akkermansia to inhibit S100A4/STAT3 pathway. International immunopharmacology. 2023;121:110548-. doi: 10.1016/j.intimp.2023.110548.
48
Shang L, Cao B*. Adapted vaccine strategy: facing the persistent challenges of COVID-19. The Lancet Infectious diseases. 2023. doi: 10.1016/s1473-3099(23)00370-5.
